Real-world analysis demonstrates sustained early and delayed responses to tralokinumab in atopic dermatitis, suggesting long-term treatment potential.
Background: An anti-interleukin-13 monoclonal antibody, tralokinumab, provided favorable efficacy and safety for atopic dermatitis (AD) in clinical trials. However, its long-term sustainability of early responses and delayed responses is unknown in real world.
No takes yet. Share an insight, caveat, or question.
Okano et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: